SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Simoncini E) "

Sökning: WFRF:(Simoncini E)

  • Resultat 1-10 av 11
  • [1]2Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Jerusalem, G, et al. (författare)
  • Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
  • 2021
  • Ingår i: Annals of Oncology. - 0923-7534. ; 32:10, s. 1256-1266
  • Tidskriftsartikel (refereegranskat)abstract
    • Late recurrences in postmenopausal women with hormone receptor-positive breast cancers remain an important challenge. Avoidance or delayed development of resistance represents the main objective in extended endocrine therapy. In animal models, resistance was reversed with restoration of circulating estrogen level during interruption of letrozole treatment. This phase 3 randomized, open-label Study of Letrozole Extension (SOLE) studied the effect of extended intermittent letrozole treatment in comparison with continuous letrozole. In parallel, the SOLE estrogen sub-study (SOLE-EST) analyzed the level of estrogen during the interruption of treatment.SOLE enrolled 4884 postmenopausal women with hormone receptor-positive, lymph node-positive, operable breast cancer between December 2007 and October 2012 and among them, 104 patients were enrolled in SOLE-EST. They must have undergone local treatment and have completed 4-6 years of adjuvant endocrine therapy. Patients were randomized between continuous letrozole (2.5 mg/day orally for 5 years) and intermittent letrozole treatment (2.5 mg/day during 9 months followed by a 3-month interruption in years 1-4 and then 2.5 mg/day during all year 5).Intention-to-treat population included 4851 women in SOLE (n=2425 in intermittent and n=2426 in continuous letrozole groups) and 103 women in SOLE-EST (n=78 in intermittent and n=25 in continuous letrozole groups). After a median follow-up of 84 months, 7-year disease-free survival was 81.4% in intermittent group and 81.5% in continuous group (hazard ratio: 1.03, 95%CI: 0.91-1.17). Reported adverse events were similar in both groups. Circulating estrogen recovery was demonstrated within 6 weeks after the stop of letrozole treatment.Extended adjuvant endocrine therapy by intermittent administration of letrozole did not improve disease-free survival compared to continuous use despite the recovery of circulating estrogen level. The similar disease-free survival coupled with previously reported quality-of-life advantages suggest intermittent extended treatment is a valid option for patients who require or prefer a treatment interruption.
  •  
2.
  • Neves-E-Castro, Manuel, et al. (författare)
  • EMAS position statement: The ten point guide to the integral management of menopausal health.
  • 2015
  • Ingår i: Maturitas. - : Elsevier. - 1873-4111. ; 81:1, s. 88-92
  • Tidskriftsartikel (refereegranskat)abstract
    • With increased longevity and more women becoming centenarians, management of the menopause and postreproductive health is of growing importance as it has the potential to help promote health over several decades. Women have individual needs and the approach needs to be personalised. The position statement provides a short integral guide for all those involved in menopausal health. It covers diagnosis, screening for diseases in later life, treatment and follow-up.
  •  
3.
  • Colleoni, M, et al. (författare)
  • Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
  • 2005
  • Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. - 0923-7534. ; 16:5, s. 716-25
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Controversy persists about whether chemotherapy benefits all breast cancer patients. PATIENTS AND METHODS: In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both. In IBCSG trial IX, 1669 postmenopausal patients with node-negative disease were randomized to receive either tamoxifen alone or three courses of adjuvant classical CMF prior to tamoxifen. Results were assessed according to estrogen receptor (ER) content of the primary tumor. RESULTS: For patients with node-positive, ER-positive disease, adding CMF either early, delayed or both reduced the risk of relapse by 21% (P=0.06), 26% (P=0.02) and 25% (P=0.02), respectively, compared with tamoxifen alone. There was no difference in disease-free survival when CMF was given prior to tamoxifen in patients with node-negative, ER-positive tumors. CONCLUSIONS: CMF given concurrently (early, delayed or both) with tamoxifen was more effective than tamoxifen alone for patients with node-positive, endocrine-responsive breast cancer, supporting late administration of chemotherapy even after commencement of tamoxifen. In contrast, sequential CMF and tamoxifen for patients with node-negative, endocrine-responsive disease was ineffective.
  •  
4.
  • Kenward, R. E., et al. (författare)
  • Identifying governance strategies that effectively support ecosystem services, resource sustainability, and biodiversity
  • 2011
  • Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : National Academy Press. - 0027-8424 .- 1091-6490. ; 108:13, s. 5308-5312
  • Tidskriftsartikel (refereegranskat)abstract
    • Conservation scientists, national governments, and international conservation groups seek to devise, and implement, governance strategies that mitigate human impact on the environment. However, few studies to date have systematically investigated the performance of different systems of governance in achieving successful conservation outcomes. Here, we use a newly-developed analytic framework to conduct analyses of a suite of case studies, linking different governance strategies to standardized scores for delivering ecosystem services, achieving sustainable use of natural resources, and conserving biodiversity, at both local and international levels. Our results: (i) confirm the benefits of adaptive management; and (ii) reveal strong associations for the role of leadership. Our work provides a critical step toward implementing empirically justified governance strategies that are capable of improving the management of human-altered environments, with benefits for both biodiversity and people.
  •  
5.
  • Aebi, S, et al. (författare)
  • Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
  • 2011
  • Ingår i: ANNALS OF ONCOLOGY. - 0923-7534. ; 22:9, s. 1981-1987
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract: Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)positive lymph node-negative breast cancer is being reassessed. Patients and methods: After stratification by ER status, 1669 postmenopausal patients with operable lymph nodenegative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF/tamoxifen) or to tamoxifen alone for 5 years. Results: ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF/tamoxifen, 66% tamoxifen; P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001). CMF had no influence on second nonbreast malignancies or deaths from other causes. Conclusion: CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherapy.
  •  
6.
  • Ferrari, P., et al. (författare)
  • Testing facility for the characterization of the integration of E-vehicles into smart grid in presence of renewable energy
  • 2019
  • Ingår i: Lecture Notes in Electrical Engineering. - : Springer Verlag. - 9783030119720 ; , s. 19-25
  • Konferensbidrag (refereegranskat)abstract
    • In the last years, the increased environmental awareness is calling for the transition from vehicles powered by Internal Combustion Engines (ICEs) toward Electric Vehicles (EVs). Nevertheless, the wide penetration of such technologies is limited by the impact EV Charging Stations (EVCSs) have on the distribution grid. The management of EVCSs could benefit from the use of the energy produced by Renewable Resources, appropriately coupled with storage system, through the infrastructures offered by Smart Grids (SGs). The validation of these architectures can be performed in simulation or emulation environments. Whilst such approaches are profitable for validating the sensitivity of different architectures to parameters changes, sometimes the use of over-simplified models could bring to unreliable results. For this reason, a testing facility for the characterization of the integration of EVCSs in SGs has been designed and deployed at the eLUX lab of the University of Brescia, Italy. The testing facility includes an EVCS (22 kW), an EV (Renault Zoe), a controllable photovoltaic (PV) field (10 kWp) and a Battery Energy Storage System (BESS) (20 kWp, 23.5 kWh). The possibility to integrate a real-time emulator (OPAL-RT) for Hardware-In-the-Loop (HIL) emulation allows to easily expand the capabilities of the testing facility. © 2019, Springer Nature Switzerland AG.
  •  
7.
  • Glasier, A, et al. (författare)
  • ISGE statement on oral emergency contraception
  • 2014
  • Ingår i: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. - 1473-0766. ; 30:10, s. 681-682
  • Tidskriftsartikel (refereegranskat)
  •  
8.
  • Gruber, G, et al. (författare)
  • Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
  • 2008
  • Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. - 1569-8041. ; 19:8, s. 1393-401
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Extracapsular tumor spread (ECS) has been identified as a possible risk factor for breast cancer recurrence, but controversy exists regarding its role in decision making for regional radiotherapy. This study evaluates ECS as a predictor of local, axillary, and supraclavicular recurrence. PATIENTS AND METHODS: International Breast Cancer Study Group Trial VI accrued 1475 eligible pre- and perimenopausal women with node-positive breast cancer who were randomly assigned to receive three to nine courses of classical combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. ECS status was determined retrospectively in 933 patients based on review of pathology reports. Cumulative incidence and hazard ratios (HRs) were estimated using methods for competing risks analysis. Adjustment factors included treatment group and baseline patient and tumor characteristics. The median follow-up was 14 years. RESULTS: In univariable analysis, ECS was significantly associated with supraclavicular recurrence (HR = 1.96; 95% confidence interval 1.23-3.13; P = 0.005). HRs for local and axillary recurrence were 1.38 (P = 0.06) and 1.81 (P = 0.11), respectively. Following adjustment for number of lymph node metastases and other baseline prognostic factors, ECS was not significantly associated with any of the three recurrence types studied. CONCLUSIONS: Our results indicate that the decision for additional regional radiotherapy should not be based solely on the presence of ECS.
  •  
9.
  •  
10.
  • Rinaldi, S., et al. (författare)
  • A Testing Framework for the Monitoring and Performance Analysis of Distributed Energy Systems
  • 2019
  • Ingår i: IEEE Transactions on Instrumentation and Measurement. - : Institute of Electrical and Electronics Engineers Inc.. - 0018-9456 .- 1557-9662. ; 68:10, s. 3831-3840
  • Tidskriftsartikel (refereegranskat)abstract
    • The increasing presence of intermittent distributed generation (DG) based on renewable energy sources (RESs) is heavily affecting the operation and management of modern distribution grids. Even though the use of distributed energy storage systems (DESSs) and the integration of advanced demand response (DR) programs are expected to mitigate this problem, security, safety, economic, and technical reasons are limiting the tests of these mechanisms in working systems. The test in simulation and emulation environments has proved to be an effective solution for the development of advanced control and protection schema, but their use for the simulation of the typically unpredictable behavior of end-users seems at least questionable. This paper proposes a testing framework for the analysis of experimental control strategies of distributed energy systems. The framework, based on a service-oriented architecture, can be easily interconnected to different systems, including renewable generators and storage systems. This framework can be used to analyze the performance of real energy systems, working in near-To-real conditions. The framework has been used for a pilot test on a subset of the facilities of the eLUX laboratory of the University of Brescia. The proposed framework allows analyzing the energy performance of this system by means of proper key performance indicators (KPIs). The efficiency analysis of a battery energy storage system (BESS) is presented, by proposing KPIs to evaluate the effect of different control strategies. Further KPIs are also used to evaluate the effectiveness of the BESS for improving the energy self-consumption of a photovoltaic system. © 1963-2012 IEEE.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 11
  • [1]2Nästa

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy